3-MeO-PCP
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
72242-03-6  91164-58-8 (hydrochloride) |
| PubChem (CID) | 11778080 |
| ChemSpider |
9952762  |
| UNII |
28A91R606X |
| Chemical and physical data | |
| Formula | C18H27NO |
| Molar mass | 273.42 g·mol−1 |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
3-Methoxyphencyclidine (3-MeO-PCP) is a dissociative anesthetic drug that has been sold online as a designer drug. The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.[1] 3-MeO-PCP binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. Though 3-MeO-PCP is often described as having opioid or dopaminergic activity,[2] this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.[3][4] 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a research chemical in 2011.[1]
3-MeO-PCP hydrochloride is a white crystalline solid with a melting point of 204-205 °C [5]
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor[3]
Legality
On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCP.[3]
Sweden's public health agency suggested classifying 3-MeO-PCP as hazardous substance on November 10, 2014.[6]
3-MeO-PCP is banned in the Czech Republic.[7]
See also
References
- 1 2 Morris, H.; Wallach, J. (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6: 614–632. doi:10.1002/dta.1620. PMID 24678061.
- ↑ Morris, H. (2011-02-11). "Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist". Vice Magazine. Retrieved 2012-01-23.
- 1 2 3 "(ACMD) Methoxetamine Report (2012)" (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2012-10-22.
- ↑ Roth, B.; Gibbons, S. (2013). "The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor=PLoS ONE". PLoS ONE. 8: e59334. doi:10.1371/journal.pone.0059334. PMC 3602154
. PMID 23527166. - ↑ Wallach J, De Paoli G, Adejare A, Brandt S (2013). "Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues". Drug Testing and Analysis. 6: 633–650. doi:10.1002/dta.1468. PMID 23554350.
- ↑ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Retrieved 29 June 2015.
- ↑ "Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení vlády č. 463/2013 Sb.)" (PDF) (in Czech). Ministerstvo zdravotnictví.